Bath & Body Works logged a -0.12% change during today's afternoon session, and is now trading at a price of $42.37 per share. The S&P 500 index moved 0.63% and the Nasdaq posted a 1.02% change.
Bath & Body Works shares moved -20.53% over the last 52 weeks, with a high of $56.96 and a low of $25.34. During this time, the stock lagged the S&P 500 index by -11.3%. As of January 2022, the company's 50-day average price is $44.05. None. The mid-cap Consumer Cyclical company is based in Columbus, OH. Bath & Body Works has returned a 1.84% dividend yield over the last 12 months.
Exceptional EPS Growth Obtained Primarily Through Share Buybacks:
| 2019-02-02 | 2020-02-01 | 2021-01-30 | 2022-01-29 | |
|---|---|---|---|---|
| Revenue (MM) | $12,852 | $12,496 | $11,356 | $7,299 |
| Revenue Growth | n/a | -2.77% | -9.12% | -35.73% |
| Gross Margins | 38.12% | 19.1% | 27.26% | 52.82% |
| Gross Margins Growth | n/a | -49.9% | 42.72% | 93.76% |
| Operating Margins | 9.62% | 8.32% | 14.12% | 27.52% |
| Operating Margins Growth | n/a | -13.51% | 69.71% | 94.9% |
| Earnings Per Share | $2.34 | -$1.32 | $3.04 | $5.25 |
| EPS Growth | n/a | -156.41% | 330.3% | 72.7% |
| Free Cash Flow (MM) | $748 | $778 | $1,811 | $1,222 |
| FCF Growth | n/a | 4.01% | 132.78% | -32.52% |
| Capital Expenditures (MM) | $629 | $458 | $228 | $270 |
| Net Debt / EBITDA | 2.4 | 5.16 | 1.65 | 1.25 |
Bath & Body Works Is Fairly Priced at Current Levels:
Compared to the Consumer Cyclical sector's average of 22.33, Bath & Body Works has a trailing twelve month P/E ratio of 12.46 and, according to its EPS guidance of 4.07, an expected P/E ratio of None.
Bath & Body Works's elevated P/B ratio notwithstanding, the company's strong cash flows, decent earnings multiple, and healthy debt levels factor towards it being fairly valued.
18 analysts are following Bath & Body Works and have set target prices ranging from $40.0 to $76.0 per share. On average, they have given the company a rating of buy. At the current price of $42.37, BBWI is trading -18.25% away from its average analyst target price of $51.83 per share, implying an analyst consensus of some upside potential for the stock.
